FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3047110054> ?p ?o ?g. }

• W3047110054 endingPage "236" @default.
• W3047110054 startingPage "230" @default.
• W3047110054 abstract "Background The present analysis aims to compare the impact of 18F-fluorocholine (18F-choline) and gallium-68 prostate-specific membrane antigen (68Ga-PSMA) positron emission tomography (PET)-computed tomography (CT)–guided metastases-directed therapies (MDTs) in patients with castration-sensitive oligorecurrent prostate cancer (PC). Materials and Methods Inclusion criteria were: (1) histologically proven prostate adenocarcinoma; (2) evidence of biochemical relapse after primary tumor treatment; (3) ≤ 3 hypermetabolic oligorecurrent lesions detected by 18F-choline or 68Ga-PSMA PET-CT; (4) PET-CT imaging performed in a single nuclear medicine department; (5) patients treated with upfront stereotactic body radiotherapy (SBRT) without hormone therapy; and (6) SBRT delivered with a dose per fraction ≥ 5 Gy. In the case of oligoprogression (≤ 3 lesions outside the previous RT field) after MTD, a further course of SBRT was proposed; otherwise, androgen deprivation therapy (ADT) was administered. Results A total of 118 lesions in 88 patients were analyzed. Forty-four (50%) patients underwent 68Ga-PSMA PET-guided SBRT, and the remaining underwent choline PET-based SBRT. The median follow-up was 25 months (range, 5-87 months) for the entire cohort. Overall survival and local control were both 100%. Distant progression occurred in 48 (54.5%) patients, for a median distant progression-free survival of 22.8 months (range, 14.4-28.8 months). The median pre-SBRT prostate-specific antigen was 2.04 ng/mL in the choline PET cohort and 0.58 ng/mL in the PSMA-PET arm. Disease-free survival rates were 63.6% and 34%, respectively, in the 68Ga-PSMA and choline PET group (P = .06). The ADT administration rate was higher after choline-PET–guided SBRT (P = .00) owing to the higher incidence of polymetastatic disease after first-course SBRT compared with 68Ga-PSMA-based SBRT. Conclusion In the setting of oligorecurrent castration-sensitive PC, PSMA-PET-guided SBRT produced a higher rate of ADT-free patients when compared with the 18F-choline-PET cohort. Randomized trials are advocated." @default.
• W3047110054 created "2020-08-10" @default.
• W3047110054 creator A5011844809 @default.
• W3047110054 creator A5016259978 @default.
• W3047110054 creator A5039338924 @default.
• W3047110054 creator A5044173595 @default.
• W3047110054 creator A5045260470 @default.
• W3047110054 creator A5046176016 @default.
• W3047110054 creator A5050362038 @default.
• W3047110054 creator A5057380847 @default.
• W3047110054 creator A5068601418 @default.
• W3047110054 creator A5070395814 @default.
• W3047110054 date "2021-06-01" @default.
• W3047110054 modified "2023-10-14" @default.
• W3047110054 title "Metastasis-directed Therapy (SBRT) Guided by PET-CT 18F-CHOLINE Versus PET-CT 68Ga-PSMA in Castration-sensitive Oligorecurrent Prostate Cancer: A Comparative Analysis of Effectiveness" @default.
• W3047110054 cites W2016190178 @default.
• W3047110054 cites W2050146329 @default.
• W3047110054 cites W2117460748 @default.
• W3047110054 cites W2150865892 @default.
• W3047110054 cites W2155263737 @default.
• W3047110054 cites W2169102736 @default.
• W3047110054 cites W2214621962 @default.
• W3047110054 cites W2278392405 @default.
• W3047110054 cites W2278701757 @default.
• W3047110054 cites W2470255787 @default.
• W3047110054 cites W2511949746 @default.
• W3047110054 cites W2574121943 @default.
• W3047110054 cites W2608885567 @default.
• W3047110054 cites W2620746860 @default.
• W3047110054 cites W2775321189 @default.
• W3047110054 cites W2805432229 @default.
• W3047110054 cites W2887800973 @default.
• W3047110054 cites W2895455649 @default.
• W3047110054 cites W2897236707 @default.
• W3047110054 cites W2916460348 @default.
• W3047110054 cites W2921789984 @default.
• W3047110054 cites W2929405676 @default.
• W3047110054 cites W2939770857 @default.
• W3047110054 cites W2947893479 @default.
• W3047110054 cites W2963794755 @default.
• W3047110054 cites W2975187676 @default.
• W3047110054 cites W2977107258 @default.
• W3047110054 cites W2998701199 @default.
• W3047110054 cites W3013251573 @default.
• W3047110054 doi "https://doi.org/10.1016/j.clgc.2020.08.002" @default.
• W3047110054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32863189" @default.
• W3047110054 hasPublicationYear "2021" @default.
• W3047110054 type Work @default.
• W3047110054 sameAs 3047110054 @default.
• W3047110054 citedByCount "48" @default.
• W3047110054 countsByYear W30471100542021 @default.
• W3047110054 countsByYear W30471100542022 @default.
• W3047110054 countsByYear W30471100542023 @default.
• W3047110054 crossrefType "journal-article" @default.
• W3047110054 hasAuthorship W3047110054A5011844809 @default.
• W3047110054 hasAuthorship W3047110054A5016259978 @default.
• W3047110054 hasAuthorship W3047110054A5039338924 @default.
• W3047110054 hasAuthorship W3047110054A5044173595 @default.
• W3047110054 hasAuthorship W3047110054A5045260470 @default.
• W3047110054 hasAuthorship W3047110054A5046176016 @default.
• W3047110054 hasAuthorship W3047110054A5050362038 @default.
• W3047110054 hasAuthorship W3047110054A5057380847 @default.
• W3047110054 hasAuthorship W3047110054A5068601418 @default.
• W3047110054 hasAuthorship W3047110054A5070395814 @default.
• W3047110054 hasConcept C121608353 @default.
• W3047110054 hasConcept C126322002 @default.
• W3047110054 hasConcept C126838900 @default.
• W3047110054 hasConcept C127077266 @default.
• W3047110054 hasConcept C2775842073 @default.
• W3047110054 hasConcept C2776235491 @default.
• W3047110054 hasConcept C2777008409 @default.
• W3047110054 hasConcept C2777899217 @default.
• W3047110054 hasConcept C2779466945 @default.
• W3047110054 hasConcept C2780192828 @default.
• W3047110054 hasConcept C2989005 @default.
• W3047110054 hasConcept C509974204 @default.
• W3047110054 hasConcept C71924100 @default.
• W3047110054 hasConceptScore W3047110054C121608353 @default.
• W3047110054 hasConceptScore W3047110054C126322002 @default.
• W3047110054 hasConceptScore W3047110054C126838900 @default.
• W3047110054 hasConceptScore W3047110054C127077266 @default.
• W3047110054 hasConceptScore W3047110054C2775842073 @default.
• W3047110054 hasConceptScore W3047110054C2776235491 @default.
• W3047110054 hasConceptScore W3047110054C2777008409 @default.
• W3047110054 hasConceptScore W3047110054C2777899217 @default.
• W3047110054 hasConceptScore W3047110054C2779466945 @default.
• W3047110054 hasConceptScore W3047110054C2780192828 @default.
• W3047110054 hasConceptScore W3047110054C2989005 @default.
• W3047110054 hasConceptScore W3047110054C509974204 @default.
• W3047110054 hasConceptScore W3047110054C71924100 @default.
• W3047110054 hasIssue "3" @default.
• W3047110054 hasLocation W30471100541 @default.
• W3047110054 hasOpenAccess W3047110054 @default.
• W3047110054 hasPrimaryLocation W30471100541 @default.
• W3047110054 hasRelatedWork W2077640666 @default.
• W3047110054 hasRelatedWork W2612014481 @default.
• W3047110054 hasRelatedWork W2772067069 @default.
• W3047110054 hasRelatedWork W2794275949 @default.

• next